MedTrace Logo

A Phase 1 Study of ABF-101 in Single- and Multiple-Ascending Doses

NCT07330674 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 68

Last updated 2026-02-06

No results posted yet for this study

Summary

This is a Phase 1 study to evaluate the safety, tolerability, PK, and PD of ABF-101 in healthy participants and participants with age-related macular degeneration (AMD).

Conditions

  • Age Related Macular Degeneration (ARMD)
  • AMD - Age-Related Macular Degeneration

Interventions

DRUG

ABF-101

orally, QD

DRUG

Placebo

orally, QD

Sponsors & Collaborators

  • Aptabio Therapeutics, Inc.

    lead INDIV

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-02-28
Primary Completion
2027-11-30
Completion
2027-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07330674 on ClinicalTrials.gov